SCHEMBL7130526

SCHEMBL7130526

Nc1nc2ccc(Cc3ccc(F)cc3)cc2s1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.73
AXL P30530 1/20 0.68
GFER P55789 1/20 0.68
NPC1 O15118 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
MAPT P10636 1/20 0.54
KCNH2 Q12809 2/20 0.52
DRD2 P14416 1/20 0.52
APP P05067 3/20 0.50
SCN4A P35499 3/20 0.50
GAA P10253 2/20 0.50
EPHX2 P34913 1/20 0.50
HTT P42858 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP3A4 P08684 5/20 0.47
HSD17B10 Q99714 3/20 0.47
TP53 P04637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13780339 0.90 RAB9A (0.81) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL1601650 0.86 RAB9A (0.75) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL27586243 0.84 RAB9A (1.00) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL21179449 0.82 AXL (0.60) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL78948 0.81 GFER (1.00) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL1913552 0.80 RAB9A (0.70) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL2918453 0.79 ALDH1A1 (0.72) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL3113690 0.78 RAB9A (0.72) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL785395 0.77 RAB9A (0.70) RAB9AAXLGFERNPC1SMN1; SMN2
SCHEMBL142514 0.77 RAB9A (1.00) RAB9AAXLGFERNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1440383-A PPAR gamma modulators SANKYO CO (JP) 2003-09-03 CN disclosed
US-20030134859-A1 PPAR-gamma modulator SANKYO COMPANY, LIMITED (JP) 2003-07-17 US disclosed
EP-1277729-A1 PPAR (GAMMA) MODULATORS Sankyo Company, Limited (JP) 2003-01-22 EP disclosed
CN-1021047-C 1,5-BENZOTHIAZEPINE DERIVATIVE AND PREPARATION THEREOF SANKYO CO (JP) 1993-06-02 CN disclosed
EP-0353032-B1 1,5-BENZOTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS Sankyo Company Limited (JP) 1992-02-26 EP disclosed
US-5002942-A Calcium channel blockers for cardiovascular disorders SANKYO COMPANY, LIMITED (JP) 1991-03-26 US disclosed
CN-1040195-A 1,5-benzo thiophene azepine derivative and its preparation method and their application in the treatment cardiovascular disorder SANKYO CO (JP) 1990-03-07 CN disclosed
EP-0353032-A1 1,5-benzothiazepine derivatives, their preparation and their use in the treatment of cardiovascular disorders Sankyo Company Limited (JP) 1990-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134859-A1 PPAR-gamma modulator PPARG, PPARA, PPARD RAB9A 1179/4885AXL 2513/4885GFER 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.